Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at Cantor Fitzgerald

Quince Therapeutics (NASDAQ:QNCX) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Weiss Ratings cut shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Wall Street Zen raised shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $44.67.

Quince Therapeutics Stock Up 4.4%

Shares of NASDAQ:QNCX opened at $0.97 on Tuesday. The company has a market cap of $15.78 million, a P/E ratio of -0.09 and a beta of 1.40. The business has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $10.53. Quince Therapeutics has a 52 week low of $0.79 and a 52 week high of $45.50.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($1.30) by $0.71.

Hedge Funds Weigh In On Quince Therapeutics

Large investors have recently bought and sold shares of the business. Bridgeway Capital Management LLC boosted its position in Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after acquiring an additional 22,200 shares during the period. XTX Topco Ltd acquired a new position in shares of Quince Therapeutics in the 2nd quarter valued at about $37,000. Intellectus Partners LLC purchased a new stake in shares of Quince Therapeutics in the fourth quarter worth approximately $179,000. GSA Capital Partners LLP boosted its holdings in shares of Quince Therapeutics by 158.0% during the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after purchasing an additional 53,417 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Quince Therapeutics during the fourth quarter worth approximately $213,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.